Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atea Pharmaceuticals reported a Q1 2024 GAAP EPS of $(0.75), missing the $(0.61) estimate by 22.95%. This represents a 74.42% increase in losses compared to the same period last year.
May 14, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atea Pharmaceuticals reported a larger than expected quarterly loss, missing analyst estimates and showing a significant increase in losses year-over-year.
Missing earnings estimates, especially with a significant increase in losses compared to the previous year, typically leads to negative investor sentiment and can result in a short-term decrease in stock price. The 22.95% miss and 74.42% increase in losses are substantial, indicating a negative outlook for AVIR in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100